Key Points
- Whitehawk insider Bryan Ball sold a total of 177,279 shares across early–mid April (including 26,389 shares on April 13 at $3.46), totaling roughly $635,055 according to SEC filings.
- The company says the disposals were made to cover tax withholding obligations related to the vesting of equity awards.
- WHWK has a market cap of about $184M, trades near its one‑year range low ($1.39) to high ($4.48), and carries a consensus analyst rating of "Hold" with an average target of $6.50.
Whitehawk Therapeutics, Inc. (NASDAQ:WHWK - Get Free Report) insider Bryan Ball sold 26,389 shares of the stock in a transaction dated Monday, April 13th. The shares were sold at an average price of $3.46, for a total value of $91,305.94. Following the completion of the transaction, the insider directly owned 489,566 shares of the company's stock, valued at $1,693,898.36. This represents a 5.11% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Bryan Ball also recently made the following trade(s):
- On Tuesday, April 14th, Bryan Ball sold 92,460 shares of Whitehawk Therapeutics stock. The shares were sold at an average price of $3.64, for a total value of $336,554.40.
- On Friday, April 10th, Bryan Ball sold 6,596 shares of Whitehawk Therapeutics stock. The shares were sold at an average price of $3.43, for a total value of $22,624.28.
- On Thursday, April 9th, Bryan Ball sold 50,000 shares of Whitehawk Therapeutics stock. The shares were sold at an average price of $3.57, for a total value of $178,500.00.
- On Monday, March 2nd, Bryan Ball sold 1,834 shares of Whitehawk Therapeutics stock. The shares were sold at an average price of $3.31, for a total value of $6,070.54.
Whitehawk Therapeutics Stock Performance
Shares of WHWK opened at $3.90 on Thursday. The company has a market capitalization of $184.07 million, a P/E ratio of 8.30 and a beta of 0.57. Whitehawk Therapeutics, Inc. has a one year low of $1.39 and a one year high of $4.48. The stock has a 50-day moving average price of $3.40 and a 200 day moving average price of $2.76.
Whitehawk Therapeutics (NASDAQ:WHWK - Get Free Report) last issued its quarterly earnings results on Thursday, March 12th. The company reported ($0.34) EPS for the quarter, beating analysts' consensus estimates of ($0.55) by $0.21.
Institutional Trading of Whitehawk Therapeutics
Several hedge funds have recently made changes to their positions in WHWK. Orbimed Advisors LLC bought a new stake in shares of Whitehawk Therapeutics in the 3rd quarter worth approximately $7,915,000. Suvretta Capital Management LLC bought a new stake in shares of Whitehawk Therapeutics in the 3rd quarter worth approximately $7,030,000. Acuta Capital Partners LLC bought a new stake in shares of Whitehawk Therapeutics in the 3rd quarter worth approximately $6,480,000. Avoro Capital Advisors LLC bought a new stake in shares of Whitehawk Therapeutics in the 3rd quarter worth approximately $5,414,000. Finally, KVP Capital Advisors LP bought a new stake in Whitehawk Therapeutics in the fourth quarter valued at $5,242,000. Institutional investors own 52.08% of the company's stock.
Analyst Ratings Changes
A number of research analysts recently commented on WHWK shares. Weiss Ratings reissued a "sell (d-)" rating on shares of Whitehawk Therapeutics in a report on Friday, March 27th. Oppenheimer started coverage on Whitehawk Therapeutics in a report on Thursday, February 5th. They set an "outperform" rating and a $6.00 target price on the stock. JonesTrading started coverage on Whitehawk Therapeutics in a report on Monday, December 22nd. They set a "buy" rating and a $7.00 target price on the stock. Finally, Wall Street Zen downgraded Whitehawk Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, April 11th. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average target price of $6.50.
Get Our Latest Analysis on Whitehawk Therapeutics
Whitehawk Therapeutics Company Profile
(
Get Free Report)
Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
